<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">GABAPENTIN<img border="0" src="../images/pr.gif"/></span><br/>(gab-a-pen'tin)<br/><span class="topboxtradename">Neurontin, Gabarone<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anticonvulsant, gaba analog</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 300 mg, 400 mg capsules; 100 mg, 300 mg, 400 mg, 600 mg, 800 mg tablets; 250 mg/5 mL solution.</p>
<h1><a name="action">Actions</a></h1>
<p>Gabapentin is a GABA neurotransmitter analog; however, it does not interact with GABA receptors, and it does not inhibit GABA
         uptake or degradation. Mechanism of action is unknown. An effect of gabapentin on central serotonin metabolism has been postulated.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Gabapentin is used in conjunction with other anticonvulsants to control certain types of seizures in patients with epilepsy.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive therapy for partial seizures with or without secondary generalization in adults, post-herpetic neuralgia.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Add-on therapy for generalized seizures, peripheral neuropathy, migraine prophylaxis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to gabapentin; pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Status epilepticus, renal impairment, older adults. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Adjunctive Therapy for Seizure Disorder</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO</span> &gt;<i>12 y</i>, Initiate with 300 mg on day 1, 300 mg b.i.d. on day 2, 300 mg t.i.d. on day 3, and continue to increase over a week to an
               initial total dose of 400 mg t.i.d. (1200 mg/d); may increase to 18002400 mg/d depending on response (most patients
               receive 9001800 mg/d in 3 divided doses) 400 mg t.i.d. (1200 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>312 y</i> Initiate with 1015 mg/kg/d in 3 divided doses, titrate q3d to target dose of 40 mg/kg/d in pts 34 y or 2535
               mg/kg/d in pts <img src="../images/special/greaterorequal.gif"/>5 y in 3 divided doses<br/><br/><span class="indicationtitle">Post-Herpetic Neuralgia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initiate with 300 mg day 1, 300 mg b.i.d. day 2, and 300 mg t.i.d. day 3; may increase up to 600 mg t.i.d. if needed<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> &gt;60 mL/min: 400 mg t.i.d.; 3060 mL/min: 300 mg b.i.d.; 1530 mL/min: 300 mg q.d.; <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Adjust dosage for patients with creatinine clearance of 60 mL/min or less. See manufacturer's recommendations.</li>
<li>Separate doses of gabapentin and antacids by 2 h.</li>
<li>Withdraw drug gradually over 1 wk; abrupt discontinuation may cause status epilepticus.</li>
<li>Store at 15°30° C (59°86° F); protect from heat, moisture, and direct light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Drowsiness, fatigue,</span> dizziness, tremor, slurred speech, impaired concentration, headache, increased frequency of partial seizures. <span class="typehead">Endocrine:</span> Weight gain. <span class="typehead">GI:</span> Nausea, gastric upset, vomiting. <span class="typehead">Special Senses:</span> Blurred vision, nystagmus, <span class="typehead">Skin:</span> Rash, eczema. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Increase in <b>phenytoin</b> levels at higher doses (300600 mg/d gabapentin). Does not appear to affect serum levels of other <span class="classification">anticonvulsants</span>. <span class="classification">antacids</span> reduce absorption of gabapentin about 20%. <span class="typehead">Herbal:</span>
<b>Ginkgo</b> may decrease anticonvulsant effectiveness. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 5060% absorbed from GI tract. <span class="typehead">Peak:</span> Peak level 13 h; peak effect 24 wk. <span class="typehead">Distribution:</span> Crosses the bloodbrain barrier comparable to other anticonvulsants; readily passes into cerebrospinal fluid; is not
      bound to plasma proteins; highest concentrations (in animal studies) found in pancreas and kidneys. <span class="typehead"> Metabolism:</span>  Does not appear to be metabolized. <span class="typehead">Elimination:</span> 7681% excreted unchanged in 96 h; 1023% recovered in feces. <span class="typehead">Half-Life:</span> 56 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness; may not occur until several weeks following initiation of therapy.</li>
<li>Assess frequency of seizures: In rare cases, the drug has increased the frequency of partial seizures.</li>
<li>Assess safety: Vision, concentration, and coordination may be impaired by gabapentin.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn potential adverse effects of drug.</li>
<li>Notify physician immediately if any of the following occur: increased seizure frequency, visual changes, unusual bruising
            or bleeding.
         </li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Do not abruptly discontinue use of drug; do not take drug within 2 h of an antacid.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>